( NYSE:ABBV )

News from AbbVie A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Feb 17, 2017, 08:00 ET AbbVie Announces $5 Billion Increase to Stock Repurchase Program

The board of directors of AbbVie Inc. (NYSE: ABBV) has authorized a $5 billion increase to AbbVie's existing stock repurchase program. Purchases...


Feb 15, 2017, 08:01 ET AbbVie to Present at the Cowen and Company 37th Annual Health Care Conference

AbbVie (NYSE: ABBV) will participate in the Cowen and Company 37th Annual Health Care Conference on Wednesday, March 8, 2017. William Chase,...


Feb 02, 2017, 08:00 ET U.S. FDA Grants Priority Review to AbbVie for its Investigational Regimen of Glecaprevir/Pibrentasvir (G/P) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6)

AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug...


Jan 27, 2017, 07:48 ET AbbVie Reports Full-Year and Fourth-Quarter 2016 Financial Results

AbbVie (NYSE:ABBV) announced financial results for the fourth quarter and full year ended December 31, 2016. "The fourth quarter was a...


Jan 25, 2017, 08:00 ET AbbVie Initiates Phase 2 Clinical Trial Programs for ABBV-8E12, an Investigational Anti-Tau Antibody, in Early Alzheimer's Disease and Progressive Supranuclear Palsy

AbbVie (NYSE: ABBV), a global biopharmaceutical company, announced the start of two Phase 2 clinical trial programs to evaluate ABBV-8E12, an...


Jan 24, 2017, 04:00 ET European Medicines Agency Grants Accelerated Assessment, Validates Marketing Authorization Application for AbbVie's Investigational Regimen of Glecaprevir/Pibrentasvir (G/P) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6)

AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that its marketing authorization application (MAA) has been validated and...


Jan 19, 2017, 07:00 ET U.S. FDA Approves IMBRUVICA® (ibrutinib) as First Treatment Specifically Indicated for Relapsed/Refractory Marginal Zone Lymphoma (MZL) - a Rare Type of Non-Hodgkin's Lymphoma

AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced the U.S. Food and Drug Administration (FDA) approved IMBRUVICA®...


Jan 10, 2017, 09:00 ET AbbVie to Host Fourth-Quarter 2016 Earnings Conference Call

AbbVie (NYSE: ABBV) will announce its Fourth-Quarter 2016 financial results on Friday, January 27, 2017. AbbVie will host a live webcast of the...


Jan 09, 2017, 08:00 ET AbbVie Announces Four New Global Research Collaborations Focused on Advancing Next-Generation Science

AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced four new collaborations and investments with leading healthcare innovators...


Jan 09, 2017, 07:00 ET Eight Weeks of Treatment with AbbVie's Investigational, Pan-Genotypic, Ribavirin-free Regimen of Glecaprevir/Pibrentasvir (G/P) for Chronic Hepatitis C Achieved High SVR[12] Rates in Genotype 1 Japanese Patients

AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced high SVR12 rates with 8 weeks of treatment with its investigational,...


Dec 22, 2016, 08:00 ET AbbVie to Present at the 35th Annual J.P. Morgan Healthcare Conference

AbbVie (NYSE: ABBV) will participate in the 35th Annual J.P. Morgan Healthcare Conference on Wednesday, Jan. 11, 2017. Richard A. Gonzalez,...


Dec 19, 2016, 08:00 ET AbbVie Submits New Drug Application to U.S. FDA for its Investigational Regimen of Glecaprevir/Pibrentasvir (G/P) for the Treatment of All Major Genotypes of Chronic Hepatitis C

AbbVie (NYSE: ABBV), a global biopharmaceutical company, announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug...


Dec 06, 2016, 10:30 ET Late-Breaking Ibrutinib (IMBRUVICA®) Data Show Complete or Partial Response in Two-Thirds of Patients with Chronic Graft-Versus-Host-Disease, a Frequent and Potentially Life-Threatening Complication of Stem Cell Transplant

AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced positive results from a Phase 2 study (PCYC-1129) evaluating ibrutinib...


Dec 05, 2016, 21:15 ET New Phase 2 Data Show Nearly Half of Patients with Relapsed/Refractory Marginal Zone Lymphoma (MZL) Respond to Treatment with Ibrutinib (IMBRUVICA®)

AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced efficacy and safety findings from a Phase 2 study demonstrating that...


Dec 05, 2016, 14:22 ET CONITEC Aprova Incorporação pelo SUS do Medicamento da AbbVie para Hepatite C Crônica

- Coformulação de ombitasvir, veruprevir/ritonavir e dasabuvir é o único tratamento oral, livre de interferon, que tem sua eficácia e segurança...


Dec 05, 2016, 08:55 ET AbbVie and Johns Hopkins to Collaborate on Cancer Research

AbbVie (NYSE: ABBV), a global biopharmaceutical company, and the Johns Hopkins University School of Medicine today announced that they signed a...


Dec 05, 2016, 08:50 ET AbbVie and Northwestern University's Lurie Cancer Center to collaborate on multi-year cancer research agreement

AbbVie (NYSE: ABBV), a global biopharmaceutical company, and Northwestern University today announced they signed a five-year collaboration...


Dec 04, 2016, 19:30 ET Favorable Response Rates Suggest Promise of Ibrutinib (IMBRUVICA®) Combination Therapy in Two Common Types of Non-Hodgkin's Lymphoma

AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced encouraging efficacy and safety findings from two separate studies...


Dec 03, 2016, 19:00 ET IMBRUVICA® (ibrutinib) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 5-Year Analysis and Long-Term RESONATE-2 Follow-up Data at ASH 2016 Show Lasting Efficacy

AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced long-term follow-up results evaluating up to five years of IMBRUVICA®...


Nov 30, 2016, 14:00 ET AbbVie Receives Orphan Drug Designation for Investigational IL-23 Inhibitor Risankizumab from the U.S. Food and Drug Administration for the Treatment of Pediatric Patients with Crohn's Disease

- Orphan Drug Designation program provides orphan status to medications intended for the safe and effective treatment, diagnosis or prevention of...


Nov 17, 2016, 08:52 ET Câncer é a Doença Mais Temida por Mais de Dois Terços da População Brasileira Revela Pesquisa DATAFOLHA

- Câncer é a principal preocupação de 65% dos brasileiros, porcentagem bem acima do número de pessoas (21%) que têm nas doenças...


Nov 15, 2016, 08:00 ET AbbVie's Investigational, Pan-Genotypic Regimen of Glecaprevir/Pibrentasvir (G/P) Shows High SVR Rates in Chronic Hepatitis C Patients with Severe Chronic Kidney Disease

AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced 98 percent (n=102/104) of chronic hepatitis C virus (HCV) infected...


Nov 14, 2016, 03:00 ET AbbVie's HUMIRA® (Adalimumab) Receives CHMP Positive Opinion to Treat Adolescents with Hidradenitis Suppurativa, a Chronic Inflammatory Skin Disease

AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the...


Nov 11, 2016, 08:00 ET Eight Weeks of Treatment with AbbVie's Investigational, Pan-Genotypic Regimen of Glecaprevir/Pibrentasvir (G/P) Achieved High SVR Rates Across All Major Genotypes of Chronic Hepatitis C

AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced high SVR12 rates with 8 weeks of treatment with its investigational,...


Nov 04, 2016, 13:33 ET AbbVie Receives FDA Orphan Drug Designation for Investigational Medicine Veliparib for the Treatment of Advanced Squamous Non-Small Cell Lung Cancer

AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug...